You have more time to weigh in on compounded GLP-1s

The FDA is weighing whether to ban large-scale compounding of semaglutide, tirzepatide, and liraglutide, a decision that could reshape access to these medications for many patients. On June 25, 2026, the agency extended the public comment period on this question, giving patients, pharmacists, and physicians more time to weigh in. If you rely on compounded versions of these drugs, or you are considering them, this decision affects what options remain available to you.

The extension gives more time to submit comments about whether semaglutide, tirzepatide, and liraglutide should remain on the FDA's list of bulk drug substances that compounding pharmacies can use under Section 503B. This list matters because it determines whether large compounding pharmacies can legally produce these medications in bulk, without an individualized prescription for each patient. If the FDA removes these substances from the list, compounding pharmacies could lose the legal basis to continue producing lower-cost versions of these GLP-1 medications at scale. That would likely narrow the options available to patients who have used compounded versions because brand-name products were too expensive or in short supply. The extended comment period, though it does not change the substance of the FDA's question, gives you more time to submit input on how this decision would affect your access to treatment.

If you have views on this issue, consider submitting a comment during the extended period. You do not need special expertise to participate. Patients who have relied on compounded semaglutide, tirzepatide, or liraglutide can describe how the decision would affect their own treatment and cost. Pharmacists and physicians can offer their professional perspective on clinical need. Either way, your input becomes part of the public record the FDA will review before making its decision.

By Amanda Bonello